Alison has a broad health law practice that encompasses counseling clients on regulatory, compliance, transactional, and legislative matters. She works with clients across the health care and life sciences sectors, including pharmaceutical and medical device manufacturers, physician practice groups, hospital systems, clinical laboratories, pharmacy benefit managers (PBMs), private equity firms, trade groups, and executives of health care entities.
Alison has extensive experience with matters involving fraud and abuse allegations, the False Claims Act, the Physician Self-Referral Law (Stark) law and related rules, the Anti-Kickback Statute, and the Beneficiary Inducements Statute. Along with representing clients in investigations and proceedings by government entities, including the Center for Medicare & Medicaid Services, and the US Department of Health and Human Services Office of Inspector General, she advocates before Congressional committees on behalf of pharmaceutical and biotechnology clients. Alison also advises clients on FDA marketing practices, HIPAA compliance, federal and state drug pricing requirements, compensation and investment arrangements, licensing, reimbursement, corporate practice of medicine rules, and transaction structures. Clients also seek her guidance on regulatory-based diligence reviews and compliance investigations.
Prior to joining Mintz, Alison was an associate at a multinational law firm, where she handled a wide range of health care regulatory and transactional matters.
While earning her JD, Alison served as an executive online editor of the Georgetown Journal of International Law and clerked in a plaintiffs’-side False Claims Act practice. She also studied at Keio University in Tokyo, Japan, where she focused on international business transactional law.
Before law school, Alison led advertising strategy for Fortune 500 consumer and health care brands.
viewpoints
PBM Policy and Legislative Update — Fall 2024
November 22, 2024 | Blog | By Rachel A. Alexander, Tara E. Dwyer, Theresa Carnegie, Bridgette Keller, Madison Castle, David Gilboa, Xavier Hardy, Samantha Hawkins, Stephnie John, Lauren Moldawer, Alison H. Peters, Abdie Santiago, Hassan Shaikh, Sophia Temis
Building upon prior issues and summarizing activity from July through September, the Fall 2024 PBM Update highlights federal legislative activity and oversight, state legislative activity and oversight, and other noteworthy events and trends affecting the PBM industry.
CMS 2026 IRA Price Negotiations Results Likely to Create Upstream and Downstream Effects
August 20, 2024 | Blog | By Rachel A. Alexander, Theresa Carnegie, Xavier Hardy, Alison H. Peters, Madison Castle
On August 15, 2024, CMS announced the results of the first round of the negotiated prices between CMS and participating drug manufacturers for the 10 selected drugs under the Inflation Reduction Act’s (IRA) Medicare Drug Price Negotiation Program (MPN or Program). In all, reactions to the MPN results varied: Reuters reported that executives from four of the manufacturers selected in the first round of negotiations stated that they do not expect the negotiated prices to significantly impact their businesses; meanwhile, in its press release announcing the maximum fair prices (MFPs), CMS touted an estimated $1.5 billion in Medicare prescription drug out-of-pocket cost savings for Medicare beneficiaries when the negotiated prices go into effect in 2026.
PBM Policy and Legislative Update — Summer 2024
July 31, 2024 | Blog | By Theresa Carnegie, Tara E. Dwyer, Rachel A. Alexander, Bridgette Keller, Madison Castle, David Gilboa, Xavier Hardy, Samantha Hawkins, Stephnie John, Pat Ouellette, Alison H. Peters, Abdie Santiago, Hassan Shaikh, Sophia Temis
Involvement
- American Bar Association, Health Law Section
- Health Law Committee, District of Columbia Bar Association (Oct. 2023 – present)
- New York Bar (2019 – present)
- District of Columbia Bar Association (2020 – present)